|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PIGO |
Gene summary for PIGO |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PIGO | Gene ID | 84720 |
| Gene name | phosphatidylinositol glycan anchor biosynthesis class O | |
| Gene Alias | HPMRS2 | |
| Cytomap | 9p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q8TEQ8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84720 | PIGO | HCC1_Meng | Human | Liver | HCC | 3.58e-46 | 7.15e-02 | 0.0246 |
| 84720 | PIGO | HCC2_Meng | Human | Liver | HCC | 1.50e-03 | 1.49e-03 | 0.0107 |
| 84720 | PIGO | S014 | Human | Liver | HCC | 5.94e-09 | 4.13e-01 | 0.2254 |
| 84720 | PIGO | S015 | Human | Liver | HCC | 3.38e-14 | 5.94e-01 | 0.2375 |
| 84720 | PIGO | S016 | Human | Liver | HCC | 4.89e-18 | 5.60e-01 | 0.2243 |
| 84720 | PIGO | S028 | Human | Liver | HCC | 7.45e-03 | 2.03e-01 | 0.2503 |
| 84720 | PIGO | S029 | Human | Liver | HCC | 4.94e-06 | 2.47e-01 | 0.2581 |
| 84720 | PIGO | C04 | Human | Oral cavity | OSCC | 2.45e-11 | 3.35e-01 | 0.2633 |
| 84720 | PIGO | C21 | Human | Oral cavity | OSCC | 1.30e-20 | 5.06e-01 | 0.2678 |
| 84720 | PIGO | C30 | Human | Oral cavity | OSCC | 7.41e-37 | 1.05e+00 | 0.3055 |
| 84720 | PIGO | C38 | Human | Oral cavity | OSCC | 1.84e-14 | 7.95e-01 | 0.172 |
| 84720 | PIGO | C43 | Human | Oral cavity | OSCC | 1.83e-04 | 1.36e-01 | 0.1704 |
| 84720 | PIGO | C46 | Human | Oral cavity | OSCC | 6.76e-15 | 2.57e-01 | 0.1673 |
| 84720 | PIGO | C51 | Human | Oral cavity | OSCC | 4.98e-04 | 1.86e-01 | 0.2674 |
| 84720 | PIGO | C57 | Human | Oral cavity | OSCC | 3.15e-07 | 1.97e-01 | 0.1679 |
| 84720 | PIGO | C06 | Human | Oral cavity | OSCC | 6.22e-04 | 4.76e-01 | 0.2699 |
| 84720 | PIGO | C08 | Human | Oral cavity | OSCC | 3.77e-10 | 1.91e-01 | 0.1919 |
| 84720 | PIGO | LN22 | Human | Oral cavity | OSCC | 2.01e-02 | 2.54e-01 | 0.1733 |
| 84720 | PIGO | LN38 | Human | Oral cavity | OSCC | 1.54e-03 | 5.97e-01 | 0.168 |
| 84720 | PIGO | LN46 | Human | Oral cavity | OSCC | 5.11e-05 | 1.78e-01 | 0.1666 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00086542 | Liver | HCC | phospholipid biosynthetic process | 150/7958 | 253/18723 | 4.77e-08 | 1.03e-06 | 150 |
| GO:00066444 | Liver | HCC | phospholipid metabolic process | 214/7958 | 383/18723 | 7.25e-08 | 1.48e-06 | 214 |
| GO:004648611 | Liver | HCC | glycerolipid metabolic process | 215/7958 | 392/18723 | 4.54e-07 | 7.49e-06 | 215 |
| GO:00421571 | Liver | HCC | lipoprotein metabolic process | 86/7958 | 135/18723 | 5.21e-07 | 8.38e-06 | 86 |
| GO:004501711 | Liver | HCC | glycerolipid biosynthetic process | 143/7958 | 252/18723 | 3.27e-06 | 4.31e-05 | 143 |
| GO:00066504 | Liver | HCC | glycerophospholipid metabolic process | 168/7958 | 306/18723 | 7.27e-06 | 8.62e-05 | 168 |
| GO:004647411 | Liver | HCC | glycerophospholipid biosynthetic process | 121/7958 | 211/18723 | 9.12e-06 | 1.06e-04 | 121 |
| GO:00066431 | Liver | HCC | membrane lipid metabolic process | 115/7958 | 203/18723 | 3.17e-05 | 3.22e-04 | 115 |
| GO:00421581 | Liver | HCC | lipoprotein biosynthetic process | 58/7958 | 96/18723 | 2.99e-04 | 2.13e-03 | 58 |
| GO:00064971 | Liver | HCC | protein lipidation | 55/7958 | 92/18723 | 6.12e-04 | 3.82e-03 | 55 |
| GO:0046467 | Liver | HCC | membrane lipid biosynthetic process | 78/7958 | 142/18723 | 1.85e-03 | 9.46e-03 | 78 |
| GO:0006664 | Liver | HCC | glycolipid metabolic process | 57/7958 | 100/18723 | 2.40e-03 | 1.17e-02 | 57 |
| GO:0006506 | Liver | HCC | GPI anchor biosynthetic process | 22/7958 | 32/18723 | 2.43e-03 | 1.18e-02 | 22 |
| GO:1903509 | Liver | HCC | liposaccharide metabolic process | 57/7958 | 101/18723 | 3.25e-03 | 1.49e-02 | 57 |
| GO:0006505 | Liver | HCC | GPI anchor metabolic process | 22/7958 | 33/18723 | 4.38e-03 | 1.90e-02 | 22 |
| GO:0006661 | Liver | HCC | phosphatidylinositol biosynthetic process | 69/7958 | 131/18723 | 1.19e-02 | 4.35e-02 | 69 |
| GO:00066432 | Oral cavity | OSCC | membrane lipid metabolic process | 111/7305 | 203/18723 | 4.02e-06 | 4.69e-05 | 111 |
| GO:00421572 | Oral cavity | OSCC | lipoprotein metabolic process | 77/7305 | 135/18723 | 1.61e-05 | 1.60e-04 | 77 |
| GO:00064972 | Oral cavity | OSCC | protein lipidation | 56/7305 | 92/18723 | 1.77e-05 | 1.72e-04 | 56 |
| GO:00086543 | Oral cavity | OSCC | phospholipid biosynthetic process | 130/7305 | 253/18723 | 3.96e-05 | 3.46e-04 | 130 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa00563 | Liver | HCC | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 18/4020 | 26/8465 | 2.08e-02 | 4.81e-02 | 2.68e-02 | 18 |
| hsa005631 | Liver | HCC | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 18/4020 | 26/8465 | 2.08e-02 | 4.81e-02 | 2.68e-02 | 18 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PIGO | SNV | Missense_Mutation | novel | c.3092C>A | p.Ala1031Asp | p.A1031D | Q8TEQ8 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-B6-A408-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
| PIGO | SNV | Missense_Mutation | c.337A>G | p.Ile113Val | p.I113V | Q8TEQ8 | protein_coding | tolerated(0.23) | benign(0) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PIGO | SNV | Missense_Mutation | novel | c.2941N>C | p.Asp981His | p.D981H | Q8TEQ8 | protein_coding | tolerated(0.05) | benign(0.026) | TCGA-XX-A89A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PIGO | insertion | Nonsense_Mutation | novel | c.1052_1053insACTGTAAGGAGGTTGGGCTGATAGGCATGTGAGTGTGTATGAGAAT | p.Glu352LeufsTer2 | p.E352Lfs*2 | Q8TEQ8 | protein_coding | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| PIGO | insertion | In_Frame_Ins | novel | c.1325_1326insCTT | p.Ser442_Trp443insPhe | p.S442_W443insF | Q8TEQ8 | protein_coding | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| PIGO | insertion | Frame_Shift_Ins | novel | c.1323_1324insGCCAGGGCCACCCCCT | p.Ser442AlafsTer69 | p.S442Afs*69 | Q8TEQ8 | protein_coding | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| PIGO | deletion | Frame_Shift_Del | c.199_205delNNNNNNN | p.Phe67GlyfsTer6 | p.F67Gfs*6 | Q8TEQ8 | protein_coding | TCGA-E9-A1R5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
| PIGO | deletion | Frame_Shift_Del | novel | c.2416delG | p.Glu806ArgfsTer7 | p.E806Rfs*7 | Q8TEQ8 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| PIGO | SNV | Missense_Mutation | rs767554501 | c.676N>A | p.Val226Met | p.V226M | Q8TEQ8 | protein_coding | deleterious(0.04) | benign(0.149) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PIGO | SNV | Missense_Mutation | rs763001837 | c.3104G>A | p.Arg1035His | p.R1035H | Q8TEQ8 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |